Singapore markets closed

Novo Nordisk A/S (0TDD.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
133.08+0.88 (+0.66%)
As of 07:10PM BST. Market open.
Full screen
Previous close132.20
Open131.85
Bid0.00 x 0
Ask0.00 x 0
Day's range131.85 - 133.16
52-week range68.37 - 142.93
Volume1,081
Avg. volume22,405
Market cap302.656B
Beta (5Y monthly)0.15
PE ratio (TTM)0.44
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Novo Nordisk A/S - share repurchase programme

    Bagsværd, Denmark, 22 July 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the programme initiat

  • GlobeNewswire

    Novo Nordisk receives Complete Response Letter in the US for once-weekly basal insulin icodec

    Bagsværd, Denmark, 10 July 2024 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) covering the Biologics License Application for once-weekly basal insulin icodec for the treatment of diabetes mellitus. In the letter, the FDA has requests related to the manufacturing process and the type 1 diabetes indication before the review of the application can be completed. Novo Nordisk is evaluating the content of the CRL and will work

  • GlobeNewswire

    Novo Nordisk stops the ocedurenone CLARION-CKD trial and recognises impairment loss

    Bagsværd, Denmark, 26 June 2024 – Novo Nordisk today announced that the CLARION-CKD phase 3 trial failed to meet its primary endpoint and that it will recognise an impairment loss of around DKK 5.7 billion related to the intangible asset ocedurenone in the second quarter of 2024. Novo Nordisk acquired ocedurenone from KBP Biosciences PTE., Ltd. in 2023. The phase 3 lead indication trial CLARION-CKD, which investigated ocedurenone in patients with uncontrolled hypertension and advanced chronic ki